메뉴 건너뛰기




Volumn 77, Issue 14, 2003, Pages 7736-7745

Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GAG PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

EID: 0038082378     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.14.7736-7745.2003     Document Type: Article
Times cited : (47)

References (48)
  • 1
    • 0033863784 scopus 로고    scopus 로고
    • Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture
    • Archer, R. H., C. Dykes, P. Gerondelis, A. Lloyd, P. Fay, R. C. Reichman, R. A. Bambara, and L. M. Demeter. 2000. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J. Virol. 74:8390-8401.
    • (2000) J. Virol. , vol.74 , pp. 8390-8401
    • Archer, R.H.1    Dykes, C.2    Gerondelis, P.3    Lloyd, A.4    Fay, P.5    Reichman, R.C.6    Bambara, R.A.7    Demeter, L.M.8
  • 2
    • 0030691001 scopus 로고    scopus 로고
    • Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase
    • Back, N. K., and B. Berkhout. 1997. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 41:2484-2491.
    • (1997) Antimicrob. Agents Chemother. , vol.41 , pp. 2484-2491
    • Back, N.K.1    Berkhout, B.2
  • 3
    • 0035104646 scopus 로고    scopus 로고
    • Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1
    • Bleiber, G., M. Munoz, A. Ciuffi, P. Meylan, and A. Telenti. 2001. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J. Virol. 75:3291-3300.
    • (2001) J. Virol. , vol.75 , pp. 3291-3300
    • Bleiber, G.1    Munoz, M.2    Ciuffi, A.3    Meylan, P.4    Telenti, A.5
  • 4
    • 0034785773 scopus 로고    scopus 로고
    • Predicting the unpredictable: Transmission of drug-resistant HIV
    • Blower, S. M., A. N. Aschenbach, H. B. Gershengorn, and J. O. Kahn. 2001. Predicting the unpredictable: transmission of drug-resistant HIV. Nat. Med. 7:1016-1020.
    • (2001) Nat. Med. , vol.7 , pp. 1016-1020
    • Blower, S.M.1    Aschenbach, A.N.2    Gershengorn, H.B.3    Kahn, J.O.4
  • 6
    • 0030065565 scopus 로고    scopus 로고
    • Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug
    • Borman, A. M., S. Paulous, and F. Clavel. 1996. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J. Gen. Virol. 77:419-426.
    • (1996) J. Gen. Virol. , vol.77 , pp. 419-426
    • Borman, A.M.1    Paulous, S.2    Clavel, F.3
  • 8
    • 0030004944 scopus 로고    scopus 로고
    • Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication
    • Caliendo, A. M., A. Savara, D. An, K. DeVore, J. C. Kaplan, and R. T. D'Aquila. 1996. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J. Virol. 70:2146-2153.
    • (1996) J. Virol. , vol.70 , pp. 2146-2153
    • Caliendo, A.M.1    Savara, A.2    An, D.3    DeVore, K.4    Kaplan, J.C.5    D'Aquila, R.T.6
  • 9
    • 0035163687 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir
    • Cote, H. C., Z. L. Brumme, and P. R. Harrigan. 2001. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75:589-594.
    • (2001) J. Virol. , vol.75 , pp. 589-594
    • Cote, H.C.1    Brumme, Z.L.2    Harrigan, P.R.3
  • 12
    • 0035158709 scopus 로고    scopus 로고
    • Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus
    • de Ronde, A., M. van Dooren, L. van Der Hoek, D. Bouwhuis, E. de Rooij, B. van Gemen, R. de Boer, and J. Goudsmit. 2001. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J. Virol. 75:595-602.
    • (2001) J. Virol. , vol.75 , pp. 595-602
    • De Ronde, A.1    Van Dooren, M.2    Van Der Hoek, L.3    Bouwhuis, D.4    De Rooij, E.5    Van Gemen, B.6    De Boer, R.7    Goudsmit, J.8
  • 13
    • 0035811838 scopus 로고    scopus 로고
    • Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants
    • Dykes, C., K. Fox, A. Lloyd, M. Chiulli, E. Morse, and L. M. Demeter. 2001. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology 285:193-203.
    • (2001) Virology , vol.285 , pp. 193-203
    • Dykes, C.1    Fox, K.2    Lloyd, A.3    Chiulli, M.4    Morse, E.5    Demeter, L.M.6
  • 14
    • 0029840781 scopus 로고    scopus 로고
    • Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection
    • Ferbas, J., E. S. Daar, K. Grovit-Ferbas, W. J. Lech, R. Detels, J. V. Giorgi, and A. H. Kaplan. 1996. Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection. J. Virol. 70:7285-7289.
    • (1996) J. Virol. , vol.70 , pp. 7285-7289
    • Ferbas, J.1    Daar, E.S.2    Grovit-Ferbas, K.3    Lech, W.J.4    Detels, R.5    Giorgi, J.V.6    Kaplan, A.H.7
  • 15
    • 0035923671 scopus 로고    scopus 로고
    • Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons
    • Garcia-Lerma, J. G., S. Nidtha, K. Blumoff, H. Weinstock, and W. Heneine. 2001. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. USA 98:13907-13912.
    • (2001) Proc. Natl. Acad. Sci. USA , vol.98 , pp. 13907-13912
    • Garcia-Lerma, J.G.1    Nidtha, S.2    Blumoff, K.3    Weinstock, H.4    Heneine, W.5
  • 16
    • 0037155193 scopus 로고    scopus 로고
    • Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors
    • Gatanaga, H., Y. Suzuki, H. Tsang, K. Yoshimura, M. F. Kavlick, K. Nagashima, R. J. Gorelick, S. Mardy, C. Tang, M. F. Summers, and H. Mitsuya. 2002. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J. Biol. Chem. 277:5952-5961.
    • (2002) J. Biol. Chem. , vol.277 , pp. 5952-5961
    • Gatanaga, H.1    Suzuki, Y.2    Tsang, H.3    Yoshimura, K.4    Kavlick, M.F.5    Nagashima, K.6    Gorelick, R.J.7    Mardy, S.8    Tang, C.9    Summers, M.F.10    Mitsuya, H.11
  • 17
    • 0034144024 scopus 로고    scopus 로고
    • Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase
    • Gotte, M., and M. A. Wainberg. 2000. Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase. Drug Resist. Update 3:30-38.
    • (2000) Drug Resist. Update , vol.3 , pp. 30-38
    • Gotte, M.1    Wainberg, M.A.2
  • 21
    • 0033762620 scopus 로고    scopus 로고
    • Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen
    • Izopet, J., P. Massip, C. Souyris, K. Sandres, B. Puissant, M. Obadia, C. Pasquier, E. Bonnet, B. Marchou, and J. Puel. 2000. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 14:2247-2255.
    • (2000) AIDS , vol.14 , pp. 2247-2255
    • Izopet, J.1    Massip, P.2    Souyris, C.3    Sandres, K.4    Puissant, B.5    Obadia, M.6    Pasquier, C.7    Bonnet, E.8    Marchou, B.9    Puel, J.10
  • 24
    • 0036888937 scopus 로고
    • Virus population homogenization following acute human immunodeficiency virus type 1 infection
    • Learn, G. H., D. Muthui, S. J. Brodie, T. Zhu, K. Diem, J. I. Mullins, and L. Corey. 1959. 2002. Virus population homogenization following acute human immunodeficiency virus type 1 infection. J. Virol. 76:11953-11959.
    • (1959) J. Virol. , vol.76 , pp. 11953-11959
    • Learn, G.H.1    Muthui, D.2    Brodie, S.J.3    Zhu, T.4    Diem, K.5    Mullins, J.I.6    Corey, L.7
  • 28
    • 0031041174 scopus 로고    scopus 로고
    • Founder virus population related to route of virus transmission: A determinant of intrahost human immunodeficiency virus type 1 evolution?
    • Lukashov, V. V., and J. Goudsmit. 1997. Founder virus population related to route of virus transmission: a determinant of intrahost human immunodeficiency virus type 1 evolution? J. Virol. 71:2023-2030.
    • (1997) J. Virol. , vol.71 , pp. 2023-2030
    • Lukashov, V.V.1    Goudsmit, J.2
  • 29
    • 0031846317 scopus 로고    scopus 로고
    • Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and Gag coevolution in protease inhibitor-treated patients
    • Mammano, F., C. Petit, and F. Clavel. 1998. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and Gag coevolution in protease inhibitor-treated patients. J. Virol. 72:7632-7637.
    • (1998) J. Virol. , vol.72 , pp. 7632-7637
    • Mammano, F.1    Petit, C.2    Clavel, F.3
  • 30
    • 0033863985 scopus 로고    scopus 로고
    • Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug
    • Mammano, F., V. Trouplin, V. Zennou, and F. Clavel. 2000. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. 74:8524-8531.
    • (2000) J. Virol. , vol.74 , pp. 8524-8531
    • Mammano, F.1    Trouplin, V.2    Zennou, V.3    Clavel, F.4
  • 31
    • 0031897794 scopus 로고    scopus 로고
    • In vivo replication capacity rather than in vitro macrophage tropism predicts efficiency of vaginal transmission of simian immunodeficiency virus or simian/human immunodeficiency virus in rhesus macaques
    • Miller, C. J., M. Marthas, J. Greenier, D. Lu, P. J. Dailey, and Y. Lu. 1998. In vivo replication capacity rather than in vitro macrophage tropism predicts efficiency of vaginal transmission of simian immunodeficiency virus or simian/human immunodeficiency virus in rhesus macaques. J. Virol. 72:3248-3258.
    • (1998) J. Virol. , vol.72 , pp. 3248-3258
    • Miller, C.J.1    Marthas, M.2    Greenier, J.3    Lu, D.4    Dailey, P.J.5    Lu, Y.6
  • 32
    • 0344766077 scopus 로고    scopus 로고
    • Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage
    • Morner, A., A. Bjorndal, J. Albert, V. N. Kewalramani, D. R. Littman, R. Inoue, R. Thorstensson, E. M. Fenyo, and E. Bjorling. 1999. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73:2343-2349.
    • (1999) J. Virol. , vol.73 , pp. 2343-2349
    • Morner, A.1    Bjorndal, A.2    Albert, J.3    Kewalramani, V.N.4    Littman, D.R.5    Inoue, R.6    Thorstensson, R.7    Fenyo, E.M.8    Bjorling, E.9
  • 34
    • 0033588178 scopus 로고    scopus 로고
    • Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors
    • Olsen, D. B., M. W. Stahlhut, C. A. Rutkowski, H. B. Schock, A. L. vanOlden, and L. C. Kuo. 1999. Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors. J. Biol. Chem. 274:23699-23701.
    • (1999) J. Biol. Chem. , vol.274 , pp. 23699-23701
    • Olsen, D.B.1    Stahlhut, M.W.2    Rutkowski, C.A.3    Schock, H.B.4    VanOlden, A.L.5    Kuo, L.C.6
  • 37
    • 0036784575 scopus 로고    scopus 로고
    • Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease
    • Pettit, S. C., G. J. Henderson, C. A. Schiffer, and R. Swanstrom. 2002. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J. Virol. 76:10226-10233.
    • (2002) J. Virol. , vol.76 , pp. 10226-10233
    • Pettit, S.C.1    Henderson, G.J.2    Schiffer, C.A.3    Swanstrom, R.4
  • 39
    • 0036337934 scopus 로고    scopus 로고
    • Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly
    • Resch, W., R. Ziermann, N. Parkin, A. Gamarnik, and R. Swanstrom. 2002. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. J. Virol. 76:8659-8666.
    • (2002) J. Virol. , vol.76 , pp. 8659-8666
    • Resch, W.1    Ziermann, R.2    Parkin, N.3    Gamarnik, A.4    Swanstrom, R.5
  • 40
    • 0034632745 scopus 로고    scopus 로고
    • HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays
    • Robinson, L. H., R. E. Myers, B. W. Snowden, M. Tisdale, and E. D. Blair. 2000. HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. AIDS Res. Hum. Retroviruses 16:1149-1156.
    • (2000) AIDS Res. Hum. Retroviruses , vol.16 , pp. 1149-1156
    • Robinson, L.H.1    Myers, R.E.2    Snowden, B.W.3    Tisdale, M.4    Blair, E.D.5
  • 46
    • 0033612928 scopus 로고    scopus 로고
    • Transmission of antiretroviral-drug-resistant HIV-1 variants
    • Yerly, S., L. Kaiser, E. Race, J. P. Bru, F. Clavel, and L. Perrin. 1999. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354:729-733.
    • (1999) Lancet , vol.354 , pp. 729-733
    • Yerly, S.1    Kaiser, L.2    Race, E.3    Bru, J.P.4    Clavel, F.5    Perrin, L.6
  • 47
    • 0036100084 scopus 로고    scopus 로고
    • Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection
    • Zhang, Y. J., T. Hatziioannou, T. Zang, D. Braaten, J. Luban, S. P. Goff, and P. D. Bieniasz. 2002. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J. Virol. 76:6332-6343.
    • (2002) J. Virol. , vol.76 , pp. 6332-6343
    • Zhang, Y.J.1    Hatziioannou, T.2    Zang, T.3    Braaten, D.4    Luban, J.5    Goff, S.P.6    Bieniasz, P.D.7
  • 48
    • 0030769354 scopus 로고    scopus 로고
    • Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
    • Zhang, Y. M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.
    • (1997) J. Virol. , vol.71 , pp. 6662-6670
    • Zhang, Y.M.1    Imamichi, H.2    Imamichi, T.3    Lane, H.C.4    Falloon, J.5    Vasudevachari, M.B.6    Salzman, N.P.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.